Erdafitinib for the treatment of urothelial cancer

References

• Nadal R, Bellmunt J. Management of metastatic bladder cancer. Cancer Treat Rev. 2019 Jun;76:10–21.
   PubMed Web of Science ®Google Scholar
• Soria F, Shariat SF, Lerner SP, et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol. 2017 Mar;35(3):379–387.
   PubMed Web of Science ®Google Scholar
• Antoni S, Ferlay J, Soerjomataram I, et al. bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017 Jan;71(1):96–108.
   PubMed Web of Science ®Google Scholar
• Cumberbatch MGK, Jubber I, Black PC, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018 Dec;74(6):784–795.
   PubMed Web of Science ®Google Scholar
• Spiess PE, Agarwal N, Bangs R, et al. Bladder cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017 Oct;15(10):1240–1267.
   PubMed Web of Science ®Google Scholar
• von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000 Sep;18(17):3068–3077.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006 Jan;42(1):50–54.
   PubMed Web of Science ®Google Scholar
• Flaig TW, Spiess PE, Agarwal N, et al. NCCN guidelines insights: bladder cancer, version 5.2018. J Natl Compr Canc Netw. 2018 Sep;16(9):1041–1053.
   PubMed Web of Science ®Google Scholar
• Necchi A, Pond GR, Raggi D, et al. Efficacy and safety of gemcitabine plus either taxane or carboplatin in the first-line setting of metastatic urothelial carcinoma: a systematic review and meta-analysis. Clin Genitourin Cancer. 2017 Feb;15(1):23–30.e2.
   PubMed Web of Science ®Google Scholar
• Powles T, Necchi A, Rosen G, et al. Anti-programmed cell death 1/ligand 1 (pd-1/pd-l1) antibodies for the treatment of urothelial carcinoma: state of the art and future development. Clin Genitourin Cancer. 2018 Apr;16(2):117–129.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009 Sep 20;27(27):4454–4461.
   PubMed Web of Science ®Google Scholar
• Grivas P, Drakaki A, Friedlander TW, et al. conceptual framework for therapeutic development beyond anti-PD-1/PD-L1 in urothelial cancer. Am Soc Clin Oncol Educ Book. 2019;39:284–300.
   PubMedGoogle Scholar
• Fradet Y, Bellmunt J, Vaughn DJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of > 2 years of follow-up. Ann Oncol. 2019 May 3.
   PubMedGoogle Scholar
• Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017 Jan 7;389(10064):67–76.
   PubMed Web of Science ®Google Scholar
• Balar AV, Castellano D, O’Donnell PH, et al. First-line pembrolizumab in cisplatin-inelegible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicenter, single-arm, phase 2 study. Lancet Oncol. 2017;18(11):1483–1492.
   PubMed Web of Science ®Google Scholar
• Sharma P, Siefker-Radtke A, de Braud F, et al. Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: checkmate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results. J Clin Oncol. 2019;37:1608–1616.
   PubMed Web of Science ®Google Scholar
• Balar AV, Mahipal A, Grande E, et al. A phase 1 study of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors. presented at: 2018 AACR Annual Meeting; 2018 April 14–18, Chicago, IL. Cancer Res. 2018;78(Suppl. 13). CT112.
   Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 7;387(10031):1909–1920.
   PubMed Web of Science ®Google Scholar
• Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2018 Aug 9;174(4):1033.
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, O’Donnell PH, Balar AV, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol. 2019 Jul 29;JCO1901140.
   PubMedGoogle Scholar
• Tagawa ST, Faltas BM, Lam ET, et al. Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): results from a phase I/II study. J Clin Oncol. 2019;37(7_suppl):354.
   Web of Science ®Google Scholar
• Touat M, Ileana E, Postel-Vinay S, et al. Targeting FGFR signaling in cancer. Clin Cancer Res. 2015 Jun 15;21(12):2684–2694.
   PubMed Web of Science ®Google Scholar
• Katoh M. Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat Rev Clin Oncol. 2019 Feb;16(2):105–122.
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Rodon J, Prat A, et al. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol. 2014 Mar;25(3):552–563.
   PubMed Web of Science ®Google Scholar
• Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010 Feb;10(2):116–129.
   PubMed Web of Science ®Google Scholar
• Perera TPS, Jovcheva E, Mevellec L, et al. Discovery and pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor. Mol Cancer Ther. 2017 Jun;16(6):1010–1020.
   PubMed Web of Science ®Google Scholar
• Bahleda R, Italiano A, Hierro C, et al. Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors. Clin Cancer Res. 2019 May 14.
   Web of Science ®Google Scholar
• Morales-Barrera R, Suarez C, de Castro AM, et al. Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: new direction and new hope. Cancer Treat Rev. 2016;50:208–216.
   PubMed Web of Science ®Google Scholar
• Nassar AH, Umeton R, Kim J, et al. Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites. Clin Cancer Res. 2019 Apr 15;25(8):2458–2470.
   PubMed Web of Science ®Google Scholar
• Ross JS, Wang K, Khaira D, et al. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. Cancer. 2016 Mar 1;122(5):702–711.
   PubMed Web of Science ®Google Scholar
• Gao Q, Liang WW, Foltz SM, et al. Driver fusions and their implications in the development and treatment of human cancers. Cell Rep. 2018 Apr 3;23(1):227–238.e3.
   PubMed Web of Science ®Google Scholar
• Robinson BD, Vlachostergios PJ, Bhinder B, et al. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun. 2019 Jul 5;10(1):2977.
   PubMed Web of Science ®Google Scholar
• Necchi A, Pal SK, Ross JS, et al. Comprehensive genomic profiling (CGP) of upper-tract (UTUC) and bladder (BUC) urothelial carcinoma reveals opportunities for therapeutic and biomarker development; poster discussion session presented at: ASCO Annual meeting; 2019 May 31 - Jun 4; Chicago, IL. J Clin Oncol. 2019;37(15_suppl):4581.
   Web of Science ®Google Scholar
• Lamont FR, Tomlinson DC, Cooper PA, et al. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer. 2011 Jan 4;104(1):75–82.
   PubMed Web of Science ®Google Scholar
• Shi MM, Linnartz R, Versace R, et al. Dovitinib (TKI258), a dual inhibitor of FGFR and VEGFR, induces tumor growth suppression in xenograft models of human bladder cancer. Cancer Res. 2011;71(8Supplement):3575 LP- 3575.
   Google Scholar
• Milowsky MI, Dittrich C, Duran I, et al. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur J Cancer. 2014 Dec;50(18):3145–3152.
   PubMed Web of Science ®Google Scholar
• Pal SK, Rosenberg JE, Hoffman-Censits JH, et al. Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discov. 2018 Jul;8(7):812–821.
   PubMed Web of Science ®Google Scholar
• Joerger M, Cassier PA, Penel N, et al. Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway. Poster discussion session presented at: ASCO Annual Meeting. 2018 Jun 1–5; Chicago, IL. J Clin Oncol. 2018;36(15_suppl):4513.
   Web of Science ®Google Scholar
• A multicenter phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the combination of rogaratinib and copanlisib in patients with FGFR-positive, locally advanced or metastatic solid tumors. Full Text View. [cited 2019 Aug 5]. Available from: ClinicalTrials.gov
   Google Scholar
• Sternberg CN, Bellmunt J, Nishiyama H, et al. Phase 2/3 study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/3 mut. Ann Oncol. 2018;29(suppl_8):viii303–viii331.
   Google Scholar
• An International, multicenter, phase 1b/2 study of rogaratinib (BAY1163877) in combination with atezolizumab as first-line treatment in cisplatin-ineligible patients with FGFR-positive locally advanced or metastatic urothelial carcinoma. Full Text View. [cited 2019 Aug 5]. Available from: ClinicalTrials.gov
   Google Scholar
• Necchi A, Pouessel D, Leibowitz-Amit R, et al. Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA); Poster session presented at: ESMO Congress. 2018 Oct 19–23; Munich, Germany. Ann Oncol. 2018;29(suppl_8):viii303–viii331.
   Google Scholar
• A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205). Full Text View. [cited 2019 Aug 5]. Available from: ClinicalTrials.gov
   Google Scholar
• Phase 2 window of opportunity study of pemigatinib in non-muscle invasive bladder cancer patients with recurrent low- or intermediate-risk tumors. Full Text View. [cited 2019 Aug 5]. Available from: ClinicalTrials.gov
   Google Scholar
• Mellado B, Castellano DE, Pang S, et al. Interim analysis of the fierce-21 phase 2 (P2) study of vofatamab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC); Poster session presented at ASCO Annual meeting; 2019 May 31 - Jun 4; Chicago, IL. J Clin Oncol. 2019;37(suppl; abstr 4547).
   PubMedGoogle Scholar
• Siefker-Radtke AO, Currie G, Abella E, et al. FIERCE-22: clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis. Poster discussion session presented at ASCO Annual meeting; 2019 May 31 - Jun 4; Chicago, IL. J Clin Oncol. 2019;37(suppl; abstr 4511).
   PubMedGoogle Scholar
• Powles T, Kilgour E, Mather R, et al. BISCAY, a phase Ib, biomarker-directed multidrug umbrella study in patients with metastatic bladder cancer; Poster session presented at ASCO Annual meeting; 2016 Jun 3–7; Chicago, IL. J Clin Oncol. 2016;34(15_suppl):TPS4577–TPS4577.
   Web of Science ®Google Scholar
• A Phase I, Gene Alteration-based, Open Label, Multicenter Study of Oral Debio 1347 (CH5183284) in Patients With Advanced Solid Malignancies, Whose Tumours Have an Alteration of the FGFR 1, 2 or 3 Genes. Full Text View. [cited 2019 Aug 5]. Available from: ClinicalTrials.gov
   Google Scholar
• A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3. Full Text View. [cited 2019 Aug 5]. Available from: ClinicalTrials.gov
   Google Scholar
• Phase 1/2 study of TAS-120 in patients with advanced solid tumors harboring FGF/FGFR aberrations. Full Text View. [cited 2019 Sep 4]. Available from: ClinicalTrials.gov
   Google Scholar
• An open-label multi-cohort phase 1b/2 study of derazantinib and atezolizumab in patients with urothelial cancer expressing activating molecular FGFR aberrations. Full Text View. [cited 2019 Sep 4]. Available from: ClinicalTrials.gov
   Google Scholar
• FDA: prescribing information for BALVERSATM (erdafitinib). 2019. [Cited 2019 Jul 28]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf
   Google Scholar
• Tabernero J, Bahleda R, Dienstmann R, et al. Phase I Dose-Escalation Study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2015 Oct 20;33(30):3401–3408.
   PubMed Web of Science ®Google Scholar
• Nishina T, Takahashi S, Iwasawa R, et al. Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors. Invest New Drugs. 2018 Jun;36(3):424–434.
   PubMed Web of Science ®Google Scholar
• Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019 Jul 25;381(4):338–348.
   PubMed Web of Science ®Google Scholar
• Loriot Y, Necchi A, Park SH, et al. Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): phase 2 continuous versus intermittent dosing. Poster session presented at: Genitourinary Cancers Symposium; 2018 Feb 8–10; San Francisco (CA). J Clin Oncol. 2018;36(6_suppl):411.
   Web of Science ®Google Scholar
• Loriot Y, Necchi A, Park SH, et al. Erdafitinib compared with vinflunine or docetaxel or pembrolizumab in patients (pts) with metastatic or surgically unresectable (M/UR) urothelial cancer. Poster session presented at: ESMO Congress. 2018 Oct 19–23; Munich, Germany. Ann Oncol. 2018;29(suppl_8):viii303–viii331.
   Google Scholar
• A phase 1b-2 study to evaluate safety, efficacy, pharmacokinetics, and pharmacodynamics of erdafitinib plus JNJ-63723283 (Cetrelimab), an anti-PD-1 monoclonal antibody, in subjects with metastatic or locally advanced urothelial cancer with selected FGFR gene alterations. Full Text View. [cited 2019 Aug 5]. Available from: ClinicalTrials.gov
   Google Scholar
• Betrian S, Gomez-Roca C, Vigarios E, et al. Severe onycholysis and eyelash trichomegaly following use of new selective pan-FGFR inhibitors. JAMA Dermatol. 2017 Jul 1;153(7):723–725.
   PubMed Web of Science ®Google Scholar
• Valade E, Dosne AG, Xie H, et al. Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure-QTc in patients with advanced or refractory solid tumors. Cancer Chemother Pharmacol. 2019 Sep;84(3):621–633.
   PubMed Web of Science ®Google Scholar
• FDA.gov: FDA approves first targeted therapy for metastatic bladder cancer[ Internet]. 2019 Apr 12. [cited 2019 Aug 5]. Available from https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-metastatic-bladder-cancer
   Google Scholar
• Santiago-Walker AE, Moy C, Cherkas Y, et al. Analysis of FGFR alterations from circulating tumor DNA (ctDNA) and tissue in a phase II trial of erdafitinib in urothelial carcinoma (UC). Poster session presented at: Genitourinary Cancers Symposium; 2019 Feb 14–16; San Francisco (CA). J Clin Oncol. 2019;37(7_suppl):420.
   Web of Science ®Google Scholar
• Wang L, Gong Y, Saci A, et al. Fibroblast growth factor receptor 3 alterations and response to PD-1/PD-L1 blockade in patients with metastatic urothelial cancer. Eur Urol. 2019 Jul 1. (Epub ahead of print).
   Web of Science ®Google Scholar
• Galsky MD, Saci A, Szabo PM, et al. Impact of Tumor Mutation Burden (TMB) on nivolumab efficacy in second-line Urothelial Carcinoma (UC) patients: exploratory analysis of the phase II checkmate 275 study. Ann Oncol. 2017;28(suppl_5):v295–329.
   Google Scholar